News & Perspective

Nov 30, 2001

Nov 30, 2001

Acambis wins new contract to supply 155 million doses of smallpox vaccine

Nov 29, 2001 (CIDRAP News) – The US Department of Health and Human Services (HHS) has awarded Acambis Inc. a $428 million contract to produce an additional 155 million doses of smallpox vaccine by the end of 2002, HHS Secretary Tommy G. Thompson announced Wednesday.

Dec 07, 2001

Dec 07, 2001

Rapid tests for environmental anthrax should not be used alone, CDC says

(CIDRAP News) – Rapid tests for detecting anthrax spores on surfaces should not be used alone as the basis for public health or clinical decisions, the Centers for Disease Control and Prevention warned in today's issue of Morbidity and Mortality Weekly Report.

Dec 13, 2001

Dec 13, 2001

House passes $2.9 billion authorization for bioterrorism preparedness

(CIDRAP News) – The US House of Representatives on Wednesday overwhelmingly approved a bill authorizing about $2.9 billion in spending on preparedness for bioterrorism and other public health emergencies.

Dec 19, 2001

Dec 19, 2001

Anthrax vaccine to be offered to postal and Capitol workers

(CIDRAP News) – Because of a small theoretical risk that anthrax spores can hide in the lungs for up to 100 days and grow after antibiotic treatment is stopped, the anthrax vaccine and an extension of antibiotic treatment will be offered to people who may have been exposed in the recent anthrax attacks, federal health officials announced yesterday afternoon.

Jan 02, 2002

Jan 02, 2002

Anthrax vaccine option has few takers so far

Jan 2, 2001 (CIDRAP News) – Aside from Capitol Hill staff members, only 52 of more than 3,500 people who have been offered the anthrax vaccine because of the recent mail attacks have decided to take it, according to the Centers for Disease Control and Prevention (CDC).

Jan 07, 2002

Jan 07, 2002

New nuclear medicine technique shows promise for early diagnosis of anthrax

(CIDRAP News) – A new nuclear medicine technique using a radioisotope-labeled antibody has shown enough promise for early diagnosis of anthrax infection to gain the Food and Drug Administration's approval for a clinical trial, according to a recent report in the Journal of Nuclear Medicine.

Jan 11, 2002

Jan 11, 2002

Five-state survey finds antibiotic-resistant enterococci in ground pork

(CIDRAP News) – A recent analysis of ground pork in grocery stores in five states showed that 4% of the samples contained enterococci with high-level resistance to gentamicin, an antibiotic used to treat enterococcal infections in humans. In addition, most Enterococcus faecium isolates were resistant to quinupristin-dalfopristin (Synercid), a streptogramin antibiotic used to treat infections caused by vancomycin-resistant E faecium.

Jan 11, 2002

Jan 11, 2002

CDC proposing to use immune globulin as treatment for severe anthrax

(CIDRAP News) – Federal health officials revealed this week that they are working on a plan to use immune globulin derived from the blood of anthrax-vaccinated military personnel for emergency treatment of patients with severe cases of inhalational anthrax, if needed.

Jan 25, 2002

Jan 25, 2002

CDC to evaluate anthrax postexposure treatment through interviews

(CIDRAP News) – Thousands of people who were potentially exposed to anthrax last fall will be interviewed over the next 8 weeks to assess the results of their postexposure antibiotic treatment, the Centers for Disease Control and Prevention (CDC) announced yesterday.

Jan 28, 2002

Jan 28, 2002

HHS to release $200 million in bioterrorism preparedness funds to states

(CIDRAP News) – The US Department of Health and Human Services (HHS) will soon release about 20% of the $1 billion in bioterrorism preparedness funding that is slated to go to states this year, HHS Secretary Tommy G. Thompson announced Jan 25.

Pages

Sort Results By:

 Sort Results By:

Narrow results by:

by Topic

by country

by organization

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation Gilead 
Grant support for ASP provided by


bioMérieux

  Become an underwriter»